Led by Dr. Larry Deeb, the TrialNet team at the TMH Physician Partners Endocrine, Diabetes and Obesity Center is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, TTMH Physician Partners Endocrine, Diabetes and Obesity Center is regionally overseen by the University of Florida. If you reach out to TrialNet, you may be contacted by staff from either institution. 

Led by Dr. Jay Shubrook, DO, the TrialNet team at Touro University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, Touro University is regionally overseen by University of California - San Francisco. If you reach out to TrialNet, you may be contacted by staff from either institution. 

Led by Cindy Chin, MD, the TrialNet team at University of Arizona Pediatric Endocrinology is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Arizona Pediatric Endocrinology is regionally overseen by University of California - San Francisco. If you reach out to TrialNet, you may be contacted by staff from either institution.

Led by Constadina Panagiotopoulos, MD, the TrialNet team at University of British Columbia is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of British Columbia is regionally overseen by The Hospital for Sick Children. If you reach out to TrialNet, you may be contacted by staff from either institution. 

University of California, San Francisco (UCSF) is one of eighteen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by Principal Investigator, Lou Philipson, MD, the TrialNet team at the University of Chicago is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Chicago is regionally overseen by Indiana University - Riley Hospital. If you reach out to TrialNet, you may be contacted by staff from either institution. 

The University of Florida (UF) is one of eighteen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Michael Haller, MD, the TrialNet team at UF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by David Baidal, MD, the TrialNet team at University of Miami is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Note: As a TrialNet affiliate, University of Miami is regionally overseen by University of Florida. If you reach out to TrialNet, you may be contacted by staff from either institution. 

Led by Inas Thomas, MD, the TrialNet team at University of Michigan is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Michigan is regionally overseen by Indiana University - Riley Hospital for Children. If you reach out to TrialNet, you may be contacted by staff from either institution. 

University of Minnesota is one of eighteen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.